Plain-English translation of NCT06984731 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a treatment plan that combines two approaches for atrial fibrillation (an irregular heartbeat condition). First, you would receive the WATCHMAN FLX device, a small umbrella-like implant that closes off a part of the heart to prevent blood clots and stroke. Second, you would have a catheter ablation procedure, which uses heat to correct the irregular heartbeat rhythm. The study wants to see if using both treatments together is safe and effective.
Atrial fibrillation puts people at high risk for both stroke and ongoing heart rhythm problems, and current treatments usually address only one of these issues. This trial exists to see if combining stroke prevention with rhythm control offers a more complete solution for patients.
You likely qualify if…
You likely don't qualify if…
You would undergo two sequential procedures: first, implantation of the WATCHMAN FLX device to seal off the left atrial appendage (preventing clot formation), and then, after healing, a catheter ablation procedure to treat your irregular heartbeat. After the procedures, you would return for follow-up visits to allow doctors to monitor your heart rhythm, check how well the device is working, and assess your overall recovery and quality of life.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China
Sponsor
Affiliated Hospital of Nantong University
Enrollment target
~210 participants
Started
April 2025
Primary completion
June 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qi Lu MD
Affiliated Hospital of Nantong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.